ProQR Therapeutics Statistics Share Statistics ProQR Therapeutics has 105.33M
shares outstanding. The number of shares has increased by 2.06%
in one year.
Shares Outstanding 105.33M Shares Change (YoY) 2.06% Shares Change (QoQ) 0.12% Owned by Institutions (%) 35.13% Shares Floating 65.1M Failed to Deliver (FTD) Shares 3,066 FTD / Avg. Volume 0.96%
Short Selling Information The latest short interest is 1.21M, so 1.14% of the outstanding
shares have been sold short.
Short Interest 1.21M Short % of Shares Out 1.14% Short % of Float 1.46% Short Ratio (days to cover) 2.99
Valuation Ratios The PE ratio is -7.53 and the forward
PE ratio is -4.02.
ProQR Therapeutics's PEG ratio is
2.63.
PE Ratio -7.53 Forward PE -4.02 PS Ratio 11.05 Forward PS 14.9 PB Ratio 2.36 P/FCF Ratio -5.53 PEG Ratio 2.63
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for ProQR Therapeutics.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 3.95,
with a Debt / Equity ratio of 0.19.
Current Ratio 3.95 Quick Ratio 3.95 Debt / Equity 0.19 Debt / EBITDA -0.71 Debt / FCF -0.46 Interest Coverage -28.29
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee $113.89K Profits Per Employee $-167.25K Employee Count 166 Asset Turnover 0.11 Inventory Turnover n/a
Taxes Income Tax -197K Effective Tax Rate 0.7%
Stock Price Statistics The stock price has increased by 25.64% in the
last 52 weeks. The beta is 0.23, so ProQR Therapeutics's
price volatility has been higher than the market average.
Beta 0.23 52-Week Price Change 25.64% 50-Day Moving Average 2.16 200-Day Moving Average 2.02 Relative Strength Index (RSI) 64.38 Average Volume (20 Days) 320,771
Income Statement In the last 12 months, ProQR Therapeutics had revenue of 18.91M
and earned -27.76M
in profits. Earnings per share was -0.34.
Revenue 18.91M Gross Profit 18.91M Operating Income -30.47M Net Income -27.76M EBITDA -24.12M EBIT -26.88M Earnings Per Share (EPS) -0.34
Full Income Statement Balance Sheet The company has 149.41M in cash and 17.22M in
debt, giving a net cash position of 132.19M.
Cash & Cash Equivalents 149.41M Total Debt 17.22M Net Cash 132.19M Retained Earnings -427.16M Total Assets 137.54M Working Capital 91.19M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -36.39M
and capital expenditures -1.42M, giving a free cash flow of -37.81M.
Operating Cash Flow -36.39M Capital Expenditures -1.42M Free Cash Flow -37.81M FCF Per Share -0.46
Full Cash Flow Statement Margins Gross margin is 100%, with operating and profit margins of -161.18% and -146.86%.
Gross Margin 100% Operating Margin -161.18% Pretax Margin -147.9% Profit Margin -146.86% EBITDA Margin -127.6% EBIT Margin -161.18% FCF Margin -200.01%
